Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 213

1.
3.
5.

A pooled data analysis on the use of intermittent cyclical etidronate therapy for the prevention and treatment of corticosteroid induced bone loss.

Adachi JD, Roux C, Pitt PI, Cooper C, Moniz C, Dequeker J, Ioannidis G, Cawley MI, Jenkins EA, Walker-Bone KE, Pack S, Stephenson GF, Laan RF, Brown J, Geusens P.

J Rheumatol. 2000 Oct;27(10):2424-31.

PMID:
11036840
6.

Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis.

Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, Kendler DL, Lentle B, Olszynski W, Ste-Marie LG, Tenenhouse A, Chines AA.

N Engl J Med. 1997 Aug 7;337(6):382-7.

7.

Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticosteroid induced osteoporosis?

Lems WF, Jacobs JW, Bijlsma JW, van Veen GJ, Houben HH, Haanen HC, Gerrits MI, van Rijn HJ.

Ann Rheum Dis. 1997 Jun;56(6):357-63.

9.
10.

Five year study of etidronate and/or calcium as prevention and treatment for osteoporosis and fractures in patients with asthma receiving long term oral and/or inhaled glucocorticoids.

Campbell IA, Douglas JG, Francis RM, Prescott RJ, Reid DM; Research Committee of the British Thoracic Society.

Thorax. 2004 Sep;59(9):761-8.

11.

Positive effect of etidronate therapy is maintained after drug is terminated in patients using corticosteroids.

Brown JP, Olszynski WP, Hodsman A, Bensen WG, Tenenhouse A, Anastassiades TP, Ste-Marie LG, Kendler DL, Hanley DA, Josse R, Hanly JG, Lentle B, Jovaisas A, Ioannidis G, Stephenson GF, Barton I, Pack S, Chines A, Dias R, Adachi JD.

J Clin Densitom. 2001 Winter;4(4):363-71.

PMID:
11748341
12.

Cyclical etidronate therapy for prevention of postmenopausal bone loss: a 1-year open-label follow-up study.

Fogelman I, Herd RJ, Blake GM, Balena R.

Calcif Tissue Int. 2000 May;66(5):348-54.

PMID:
10773104
13.

Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss.

Adachi J, Cranney A, Goldsmith CH, Bensen WG, Bianchi F, Cividino A, Craig GL, Kaminska E, Sebaldt RJ, Papaioannou A, et al.

J Rheumatol. 1994 Oct;21(10):1922-6.

PMID:
7837160
14.

Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment.

Miller PD, Watts NB, Licata AA, Harris ST, Genant HK, Wasnich RD, Ross PD, Jackson RD, Hoseyni MS, Schoenfeld SL, Valent DJ, Chesnut CH 3rd.

Am J Med. 1997 Dec;103(6):468-76. Erratum in: m J Med 1998 Jun;104(6):608.

PMID:
9428829
15.

Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women.

Diamond T, McGuigan L, Barbagallo S, Bryant C.

Am J Med. 1995 May;98(5):459-63.

PMID:
7733124
16.

Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy.

Harris ST, Watts NB, Jackson RD, Genant HK, Wasnich RD, Ross P, Miller PD, Licata AA, Chesnut CH 3rd.

Am J Med. 1993 Dec;95(6):557-67.

PMID:
8259772
17.

Intermittent cyclical etidronate treatment of postmenopausal osteoporosis.

Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson GC 3rd, Yanover MJ, et al.

N Engl J Med. 1990 Jul 12;323(2):73-9.

18.
19.

The effects of cyclical etidronate on early postmenopausal bone loss: an open, randomized controlled study.

Heath DA, Bullivant BG, Boiven C, Balena R.

J Clin Densitom. 2000 Spring;3(1):27-33.

PMID:
10745299
20.

Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy.

Reid DM, Adami S, Devogelaer JP, Chines AA.

Calcif Tissue Int. 2001 Oct;69(4):242-7.

PMID:
11730260
Items per page

Supplemental Content

Write to the Help Desk